Vistogard
Term · Oncology and biomedicine · MLC-T-ONC-009272
A drug used in the emergency treatment of adults and children who receive too much fluorouracil or capecitabine or who have heart or central nervous system toxicity or other serious side effects that occur within 4 days of ending treatment with these drugs. Vistogard may help protect healthy cells from some of the side effects caused by certain anticancer drugs. It is a type of chemoprotective agent and a type of pyrimidine analog. Also called PN401, triacetyluridine, and uridine triacetate.
| Identifier | MLC-T-ONC-009272 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | PN401; triacetyluridine; uridine triacetate |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-009272",
"term": "Vistogard",
"field": "Oncology and biomedicine",
"definition": "A drug used in the emergency treatment of adults and children who receive too much fluorouracil or capecitabine or who have heart or central nervous system toxicity or other serious side effects that occur within 4 days of ending treatment with these drugs. Vistogard may help protect healthy cells from some of the side effects caused by certain anticancer drugs. It is a type of chemoprotective agent and a type of pyrimidine analog. Also called PN401, triacetyluridine, and uridine triacetate.",
"synonyms": [
"PN401",
"triacetyluridine",
"uridine triacetate"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/vistogard/"
}
Record 17,272 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.